[Evaluation of cellular immunity in pulmonary sarcoidosis and primary lung cancer].
We tested the cellular immunity of the patients with pulmonary sarcoidosis (n = 16) and primary lung cancer (n = 14). The data showed that PHA-p induced peripheral blood lymphocyte (PBL) proliferation and interleukin 2 (IL-2) productivity were significantly reduced in both patients groups, and also the PBL proliferation induced by exogenous recombined IL-2 was reduced, but not significantly (P > 0.05) compared with normal central. Our results suggested that cellular immunodepression may exist in pulmonary sarcoidosis and primary lung cancer patients, the exogenous IL-2 can partly restore the reduced PBL proliferation. So the cytokine may play a role in the immunologic treatment of lung cancer and the research of pulmonary sarcoidosis.
Li
J P
JP
Department of Medicine, Peking Union Medical College Hospital.
D000328:Adult; D000368:Aged; D018288:Carcinoma, Small Cell / Q000276:immunology / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000628:therapy; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007376:Interleukin-2 / Q000096:biosynthesis* / Q000627:therapeutic use; D008171:Lung Diseases / Q000276:immunology* / Q000628:therapy; D008175:Lung Neoplasms / Q000276:immunology* / Q000628:therapy; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D012507:Sarcoidosis / Q000276:immunology* / Q000628:therapy
D007376:Interleukin-2